News

After approximately $3.7 billion in acquisitions, Amgen will own the rights to Tavneos (avacopan), an approved oral therapy developed by ChemoCentryx to treat ANCA-associated vasculitis (AAV). Amgen is acquiring ChemoCentryx in a cash deal, expected to be completed by year’s end, the companies announced. “The acquisition of ChemoCentryx represents a…

An increase in ANCA antibodies may predict a relapse within six to 12 months in people with ANCA-associated vasculitis (AAV), according to a new study. The link between an antibody rise and AAV relapse was found to be significant in patients with myeloperoxidase (MPO)-ANCAs, or antibodies against…

A combination of lab tests commonly used to diagnose ANCA-associated vasculitis (AAV) may be able to accurately predict the long-term prognosis of patients and maybe select those needing more aggressive treatment, according to a 15-year study in China. The study, “Long-Term Prognostic Factors in Patients With Antineutrophil…

Similar to neutrophils, immune monocyte cells play an essential role in kidney damage caused by ANCA-associated vasculitis (AAV), a study discovered. The pro-inflammatory function of monocytes was stimulated by the immune signaling protein CSF2, also called GM-CSF. Therapeutically targeting monocytes or CSF2 may be a potential new treatment strategy…

A woman developed a rare case of acute kidney failure linked to ANCA-associated vasculitis (AAV) following her first dose of the Pfizer-BioNTech COVID-19 vaccine, according to a report. This case adds to previous reports suggesting that COVID-19 vaccines may, in rare instances, promote the development or exacerbation of autoimmune…

Treatment with rituximab helps most adults, ages 75 and older, with ANCA-associated vasculitis (AAV) achieve and maintain disease remission, a French study found. However, a higher rate of serious infections and deaths were reported when rituximab was used as an induction therapy, in combination with high doses of glucocorticoids,…

Excess of a particular amino acid, or protein building block, in the blood may make neutrophils — a type of white blood cell that first responds to an infection or injury — more reactive in ANCA-associated vasculitis (AAV) and large-vessel vasculitis, a study has found. The amino acid, called…

The Johnson & Johnson COVID-19 vaccine may have triggered kidney inflammation associated with ANCA-associated vasculitis (AAV) in a 52-year-old woman, according to a recent case report. “We believe that this is the first case report of AAV that occurred following adenovirus vector COVID-19 vaccine administration,” its scientists wrote. “Increasing…

Measuring the blood levels of a protein called BAFF could help predict the chances of remission after induction treatment with rituximab in people with ANCA vasculitis (AAV), according to a new study. Determining the BAFF levels in the blood also could guide further care for AAV patients, the researchers…

Nonprofits, scientists, governmental organizations, and the rare disease drug development industry have long cited 7,000 as the average number of rare diseases in the world. But a new analysis shows there are as many as 10,867 rare diseases globally. And that…